Literature DB >> 10821442

Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain.

M Mogi1, A Togari, T Kondo, Y Mizuno, O Komure, S Kuno, H Ichinose, T Nagatsu.   

Abstract

The activities of caspase-1 and caspase-3 were measured by use of fluoropeptides as substrates for the first time in the brain (substantia nigra, caudate nucleus, putamen, cerebellum, and frontal cortex) from control and parkinsonian patients. The activities of caspases in the brain were significantly higher in the substantia nigra from parkinsonian patients than those in the brain from control patients (p < 0.01). However, the activities of caspases in the caudate nucleus, putamen, cerebellum, and frontal cortex showed no significant difference between parkinsonian and control patients. The tumor necrosis factor (TNF) receptor R1 (TNF-R1, p55) level was also elevated in the substantia nigra of the parkinsonian brain in comparison with that of controls (p < 0.05). Since both caspases and TNF-R1 may play important roles in apoptotic cell death through TNF-alpha-induced signaling pathway, our present data suggest the presence of a proapoptotic environment in the substantia nigra of parkinsonian brain, probably inducing vulnerability of neurons and glias towards a variety of noxious factors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10821442     DOI: 10.1007/s007020050028

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  68 in total

1.  Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis.

Authors:  A Hartmann; J D Troadec; S Hunot; K Kikly; B A Faucheux; A Mouatt-Prigent; M Ruberg; Y Agid; E C Hirsch
Journal:  J Neurosci       Date:  2001-04-01       Impact factor: 6.167

Review 2.  Emerging therapies in the pharmacological treatment of Parkinson's disease.

Authors:  Amos D Korczyn; Miri Nussbaum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Glial cell response: A pathogenic factor in Parkinson's disease.

Authors:  Du Chu Wu; Kim Tieu; Oren Cohen; Dong-Kug Choi; Miquel Vila; Vernice Jackson-Lewis; Peter Teismann; Serge Przedborski
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

4.  Chronic dichlorvos exposure: microglial activation, proinflammatory cytokines and damage to nigrostriatal dopaminergic system.

Authors:  B K Binukumar; Amanjit Bal; Kiran Dip Gill
Journal:  Neuromolecular Med       Date:  2011-10-04       Impact factor: 3.843

5.  Nurr1 and PPARγ protect PC12 cells against MPP(+) toxicity: involvement of selective genes, anti-inflammatory, ROS generation, and antimitochondrial impairment.

Authors:  Mohammad Jodeiri Farshbaf; Mahboobeh Forouzanfar; Kamran Ghaedi; Abbas Kiani-Esfahani; Maryam Peymani; Alireza Shoaraye Nejati; Tayebeh Izadi; Khadijeh Karbalaie; Maryam Noorbakhshnia; Soheila Rahgozar; Hossein Baharvand; Mohammad Hossein Nasr-Esfahani
Journal:  Mol Cell Biochem       Date:  2016-07-19       Impact factor: 3.396

6.  Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.

Authors:  Melissa K McCoy; Terina N Martinez; Kelly A Ruhn; David E Szymkowski; Christine G Smith; Barry R Botterman; Keith E Tansey; Malú G Tansey
Journal:  J Neurosci       Date:  2006-09-13       Impact factor: 6.167

Review 7.  Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases.

Authors:  Kathryn A Frankola; Nigel H Greig; Weiming Luo; David Tweedie
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-05       Impact factor: 4.388

8.  Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons.

Authors:  Italo Mocchetti; Alessia Bachis; Rachel L Nosheny; Gianluigi Tanda
Journal:  Neurotox Res       Date:  2007-09       Impact factor: 3.911

Review 9.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

Review 10.  Programmed cell death in Parkinson's disease.

Authors:  Katerina Venderova; David S Park
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.